Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 9Completed 6Withdrawn 4Terminated 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 17CNS 12Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 70Carcinoma, Neuroendocrine 7Gastro-enteropancreatic neuroendocrine tumor 6Carcinoid Tumor 6Neoplasm Metastasis 5Paraganglioma 3Pancreatic Neoplasms 3Carcinoma, Hepatocellular 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Teratoma 1Small Intestinal Neuroendocrine Tumor 1Small Cell Lung Carcinoma 1Rectal Neuroendocrine Tumor 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 1Pancreatic Neuroendocrine Tumors in MEN1 1Osteomalacia 1Neuroendocrine Tumors With Metastasis 1Neuroendocrine Tumors Metastatic to the Liver 1Neuroendocrine Tumor Grade 3 1Neuroblastoma 1

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pheochromocytoma × NET × Clear all
NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡